Membranoproliferative glomerulonephritis causes: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Membranoproliferative glomerulonephritis}}
{{Membranoproliferative glomerulonephritis}}
{{CMG}}
{{CMG}}{{APM}} {{AE}}{{OO}}
==Overview==
==Overview==
==Causes==
==Causes==

Revision as of 19:08, 30 January 2017

Membranoproliferative glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Membranoproliferative glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Membranoproliferative glomerulonephritis causes On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis causes

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Membranoproliferative glomerulonephritis causes

CDC on Membranoproliferative glomerulonephritis causes

Membranoproliferative glomerulonephritis causes in the news

Blogs on Membranoproliferative glomerulonephritis causes

Directions to Hospitals Treating Membranoproliferative glomerulonephritis

Risk calculators and risk factors for Membranoproliferative glomerulonephritis causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2] Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]

Overview

Causes

Conditions associated with a membranoproliferative pattern of injury are listed as follows:

  • Immune complex–mediated disease
  • Idiopathic forms of MPGN or of unknown association
    • MPGN type I
    • MPGN type II or dense deposit disease and PLD
    • MPGN type III
  • Autoimmune diseases
    • Systemic lupus erythematosus (SLE)
    • Sjögren syndrome
    • Rheumatoid arthritis
    • Inherited complement deficiencies, in particular, C2 deficiency
    • Scleroderma
    • Celiac disease
  • Chronic infections
    • Viral - Hepatitis B, hepatitis C, and cryoglobulinemia type II
    • Bacterial - Endocarditis, infected ventriculoatrial (or jugular) shunt, multiple visceral abscesses, leprosy
    • Protozoal - Malaria, schistosomiasis
    • Other infections - Mycoplasma
  • Miscellaneous - Chronic liver disease (cirrhosis and alpha1-antitrypsin deficiency)
  • Chronic and recovered thrombotic microangiopathies
  • Healing phase of hemolytic uremic syndrome and/or thrombotic thrombocytopenic purpura
  • Syndromes of circulating antiphospholipid (anticardiolipin) antibodies
  • Radiation nephritis
  • Nephropathy associated with bone marrow transplantation
  • Sickle cell anemia and polycythemia
  • Transplant glomerulopathy
  • Paraprotein deposition diseases
  • Glomerulonephropathies associated with cryoglobulinemia type I
  • Waldenström macroglobulinemia
  • Immunotactoid glomerulopathy
  • Immunoglobulin light chain or heavy chain deposition diseases
  • Fibrillary glomerulonephritis
  • Malignant neoplasms
  • Lymphoma
  • Leukemia
  • Carcinoma

References

Template:WH Template:WS